ArticleTranslational oncology2020

RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS-mutant colorectal cancer.

Tonći Šuštić et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.